PMID- 26364276
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181113
IS  - 1469-5111 (Electronic)
IS  - 1461-1457 (Print)
IS  - 1461-1457 (Linking)
VI  - 19
IP  - 3
DP  - 2015 Sep 12
TI  - S100B Serum Levels Predict Treatment Response in Patients with Melancholic 
      Depression.
PG  - pyv103
LID - pyv103 [pii]
LID - 10.1093/ijnp/pyv103 [doi]
AB  - BACKGROUND: There is an ongoing search for biomarkers in psychiatry, for example, 
      as diagnostic tools or predictors of treatment response. The neurotrophic factor 
      S100 calcium binding protein B (S100B) has been discussed as a possible predictor 
      of antidepressant response in patients with major depression, but also as a 
      possible biomarker of an acute depressive state. The aim of the present study was 
      to study the association of serum S100B levels with antidepressant treatment 
      response and depression severity in melancholically depressed inpatients. 
      METHODS: After a wash-out period of 1 week, 40 inpatients with melancholic 
      depression were treated with either venlafaxine or imipramine. S100B levels and 
      Hamilton Depression Rating Scale (HAM-D) scores were assessed at baseline, after 
      7 weeks of treatment, and after 6 months. RESULTS: Patients with high S100B 
      levels at baseline showed a markedly better treatment response defined as 
      relative reduction in HAM-D scores than those with low baseline S100B levels 
      after 7 weeks (P=.002) and 6 months (P=.003). In linear regression models, S100B 
      was a significant predictor for treatment response at both time points. It is of 
      interest to note that nonresponders were detected with a predictive value of 85% 
      and a false negative rate of 7.5%. S100B levels were not associated with 
      depression severity and did not change with clinical improvement. CONCLUSIONS: 
      Low S100B levels predict nonresponse to venlafaxine and imipramine with high 
      precision. Future studies have to show which treatments are effective in patients 
      with low levels of S100B so that this biomarker will help to reduce patients' 
      burden of nonresponding to frequently used antidepressants.
CI  - (c) The Author 2015. Published by Oxford University Press on behalf of CINP.
FAU - Ambree, Oliver
AU  - Ambree O
AD  - Department of Psychiatry, University of Munster, Germany (Dr Ambree, Ms Grosse, 
      Dr Alferink, Dr Rothermundt, and Dr Arolt); Department of Psychiatry, Erasmus 
      Medical Center Rotterdam, The Netherlands (Drs Bergink and Birkenhager); 
      Radiology Morphological Solutions, Rotterdam, The Netherlands (Ms Grosse); 
      Department of Immunology, Erasmus Medical Center Rotterdam, The Netherlands (Dr 
      Drexhage); Cluster of Excellence EXC 1003, Cells in Motion, Munster, Germany (Dr 
      Alferink); Department of Psychiatry, St. Rochus-Hospital, Telgte, Oberhausen, 
      Germany (Dr Rothermundt). ambree@uni-muenster.de.
FAU - Bergink, Veerle
AU  - Bergink V
AD  - Department of Psychiatry, University of Munster, Germany (Dr Ambree, Ms Grosse, 
      Dr Alferink, Dr Rothermundt, and Dr Arolt); Department of Psychiatry, Erasmus 
      Medical Center Rotterdam, The Netherlands (Drs Bergink and Birkenhager); 
      Radiology Morphological Solutions, Rotterdam, The Netherlands (Ms Grosse); 
      Department of Immunology, Erasmus Medical Center Rotterdam, The Netherlands (Dr 
      Drexhage); Cluster of Excellence EXC 1003, Cells in Motion, Munster, Germany (Dr 
      Alferink); Department of Psychiatry, St. Rochus-Hospital, Telgte, Oberhausen, 
      Germany (Dr Rothermundt).
FAU - Grosse, Laura
AU  - Grosse L
AD  - Department of Psychiatry, University of Munster, Germany (Dr Ambree, Ms Grosse, 
      Dr Alferink, Dr Rothermundt, and Dr Arolt); Department of Psychiatry, Erasmus 
      Medical Center Rotterdam, The Netherlands (Drs Bergink and Birkenhager); 
      Radiology Morphological Solutions, Rotterdam, The Netherlands (Ms Grosse); 
      Department of Immunology, Erasmus Medical Center Rotterdam, The Netherlands (Dr 
      Drexhage); Cluster of Excellence EXC 1003, Cells in Motion, Munster, Germany (Dr 
      Alferink); Department of Psychiatry, St. Rochus-Hospital, Telgte, Oberhausen, 
      Germany (Dr Rothermundt).
FAU - Alferink, Judith
AU  - Alferink J
AD  - Department of Psychiatry, University of Munster, Germany (Dr Ambree, Ms Grosse, 
      Dr Alferink, Dr Rothermundt, and Dr Arolt); Department of Psychiatry, Erasmus 
      Medical Center Rotterdam, The Netherlands (Drs Bergink and Birkenhager); 
      Radiology Morphological Solutions, Rotterdam, The Netherlands (Ms Grosse); 
      Department of Immunology, Erasmus Medical Center Rotterdam, The Netherlands (Dr 
      Drexhage); Cluster of Excellence EXC 1003, Cells in Motion, Munster, Germany (Dr 
      Alferink); Department of Psychiatry, St. Rochus-Hospital, Telgte, Oberhausen, 
      Germany (Dr Rothermundt).
FAU - Drexhage, Hemmo A
AU  - Drexhage HA
AD  - Department of Psychiatry, University of Munster, Germany (Dr Ambree, Ms Grosse, 
      Dr Alferink, Dr Rothermundt, and Dr Arolt); Department of Psychiatry, Erasmus 
      Medical Center Rotterdam, The Netherlands (Drs Bergink and Birkenhager); 
      Radiology Morphological Solutions, Rotterdam, The Netherlands (Ms Grosse); 
      Department of Immunology, Erasmus Medical Center Rotterdam, The Netherlands (Dr 
      Drexhage); Cluster of Excellence EXC 1003, Cells in Motion, Munster, Germany (Dr 
      Alferink); Department of Psychiatry, St. Rochus-Hospital, Telgte, Oberhausen, 
      Germany (Dr Rothermundt).
FAU - Rothermundt, Matthias
AU  - Rothermundt M
AD  - Department of Psychiatry, University of Munster, Germany (Dr Ambree, Ms Grosse, 
      Dr Alferink, Dr Rothermundt, and Dr Arolt); Department of Psychiatry, Erasmus 
      Medical Center Rotterdam, The Netherlands (Drs Bergink and Birkenhager); 
      Radiology Morphological Solutions, Rotterdam, The Netherlands (Ms Grosse); 
      Department of Immunology, Erasmus Medical Center Rotterdam, The Netherlands (Dr 
      Drexhage); Cluster of Excellence EXC 1003, Cells in Motion, Munster, Germany (Dr 
      Alferink); Department of Psychiatry, St. Rochus-Hospital, Telgte, Oberhausen, 
      Germany (Dr Rothermundt).
FAU - Arolt, Volker
AU  - Arolt V
AD  - Department of Psychiatry, University of Munster, Germany (Dr Ambree, Ms Grosse, 
      Dr Alferink, Dr Rothermundt, and Dr Arolt); Department of Psychiatry, Erasmus 
      Medical Center Rotterdam, The Netherlands (Drs Bergink and Birkenhager); 
      Radiology Morphological Solutions, Rotterdam, The Netherlands (Ms Grosse); 
      Department of Immunology, Erasmus Medical Center Rotterdam, The Netherlands (Dr 
      Drexhage); Cluster of Excellence EXC 1003, Cells in Motion, Munster, Germany (Dr 
      Alferink); Department of Psychiatry, St. Rochus-Hospital, Telgte, Oberhausen, 
      Germany (Dr Rothermundt).
FAU - Birkenhager, Tom K
AU  - Birkenhager TK
AD  - Department of Psychiatry, University of Munster, Germany (Dr Ambree, Ms Grosse, 
      Dr Alferink, Dr Rothermundt, and Dr Arolt); Department of Psychiatry, Erasmus 
      Medical Center Rotterdam, The Netherlands (Drs Bergink and Birkenhager); 
      Radiology Morphological Solutions, Rotterdam, The Netherlands (Ms Grosse); 
      Department of Immunology, Erasmus Medical Center Rotterdam, The Netherlands (Dr 
      Drexhage); Cluster of Excellence EXC 1003, Cells in Motion, Munster, Germany (Dr 
      Alferink); Department of Psychiatry, St. Rochus-Hospital, Telgte, Oberhausen, 
      Germany (Dr Rothermundt).
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150912
PL  - England
TA  - Int J Neuropsychopharmacol
JT  - The international journal of neuropsychopharmacology
JID - 9815893
RN  - 0 (Antidepressive Agents)
RN  - 0 (Biomarkers)
RN  - 0 (S100 Calcium Binding Protein beta Subunit)
RN  - 0 (S100B protein, human)
RN  - 7D7RX5A8MO (Venlafaxine Hydrochloride)
RN  - OGG85SX4E4 (Imipramine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antidepressive Agents/*therapeutic use
MH  - Biomarkers/blood
MH  - Blood Chemical Analysis
MH  - Depressive Disorder/*blood/diagnosis/*drug therapy
MH  - False Negative Reactions
MH  - Female
MH  - Humans
MH  - Imipramine/*therapeutic use
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Psychiatric Status Rating Scales
MH  - S100 Calcium Binding Protein beta Subunit/*blood
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
MH  - Venlafaxine Hydrochloride/*therapeutic use
PMC - PMC4815471
OTO - NOTNLM
OT  - Major depression
OT  - antidepressant response
OT  - neurotrophic factor
OT  - predictive biomarker
OT  - treatment resistance
EDAT- 2015/09/14 06:00
MHDA- 2016/12/15 06:00
PMCR- 2015/09/12
CRDT- 2015/09/14 06:00
PHST- 2015/05/19 00:00 [received]
PHST- 2015/09/03 00:00 [accepted]
PHST- 2015/09/14 06:00 [entrez]
PHST- 2015/09/14 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
PHST- 2015/09/12 00:00 [pmc-release]
AID - pyv103 [pii]
AID - 10.1093/ijnp/pyv103 [doi]
PST - epublish
SO  - Int J Neuropsychopharmacol. 2015 Sep 12;19(3):pyv103. doi: 10.1093/ijnp/pyv103.